What is the NOAEL for Tazarotene?
Tazarotene has 42 NOAEL studies in the database. The lowest reported value is 81BDR9Y8PS UNII. Source: openFDA substances.
NOAEL Data
Cosmetic Ingredient
Tazarotene
Also known as: Tazorac, UNII-81BDR9Y8PS
CAS 118292-40-3
Tazarotene (CAS 118292-40-3) is a chemical substance. Key regulatory status: 4 regulatory/inventory lists, cosmetic ingredient cross-reference; source data from EPA ToxValDB, EPA CPDat.
SOURCE
noael studies public
NOAEL studies
42
SOURCE
chemical inventory jurisdictions
Regulatory lists
4
SOURCE
eu clp annex vi
GHS signal
Not classified
Chemical Identity
CAS, identifiers, formula, and alternate names for the matched substance record.
SOURCE
DSSTox identifiers
8 fields
Name
Tazarotene
CAS Number
118292-40-3
DTXSID
DTXSID5046691
Molecular Formula
C21H21NO2S
InChI Key
OGQICQVSFDPSEI-UHFFFAOYSA-N
Monoisotopic Mass
351.1293
Synonyms
TazoracUNII-81BDR9Y8PS
Functional Uses
Industrial and product-use categories associated with this substance.
SOURCE
EPA CPDat
1 records
Softener and conditioner
Regulatory Lists
Inventory, screening, and regulatory list matches from public chemical databases.
SOURCE
EPA CPDat
4 records
| List | Keyword | Source |
|---|---|---|
| Canada; consumer_product; Substances in Products - Canada (4/2014) | Government of Canada | CPCat |
| pharmaceutical | US International Trade Commission | CPCat |
| Canada; pharmaceutical | DrugBank | DrugBank |
| Canada; pharmaceutical | DrugBank | DrugBank |
NOAEL Studies
Toxicology endpoints rendered from public NOAEL study rows.
SOURCE
NOAEL studies
Showing 42 of 42 studies
| Value | Unit | Endpoint | Route | Species | Source |
|---|---|---|---|---|---|
| 81BDR9Y8PS | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| 81BDR9Y8PS | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| 81BDR9Y8PS | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| 81BDR9Y8PS | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| >=0.025 | mg/kg bw/day | LEL | oral | Rat | ToxValDB_ECHA_IUCLID |
| >=0.05 | mg/kg bw/day | LEL | oral | Rat | ToxValDB_ECHA_IUCLID |
| >=0.1 | mg/kg bw/day | LEL | oral | Rat | ToxValDB_ECHA_IUCLID |
| =0.125 | mg/kg bw/day | LEL | oral | Rat | ToxValDB_ECHA_IUCLID |
| >=0.25 | mg/kg bw/day | LEL | dermal | Pig | ToxValDB_ECHA_IUCLID |
| =0.5 | mg/kg bw/day | LEL | oral | Rat | ToxValDB_ECHA_IUCLID |
| =1.6 | mg/kg bw/day | LEL | oral | Monkey | ToxValDB_ECHA_IUCLID |
| =2 | mg/kg bw/day | LEL | oral | Rat | ToxValDB_ECHA_IUCLID |
| <=0.05 | % | NOEL | dermal | mouse (CD-1; male/female) | FDA_Toxicity_c3e27a4e-2099-431d-aab3-92c709024c1d_dossier.i6z |
| <=0.05 | mg/kg bw/day | NOEL | dermal | rat (Sprague-Dawley; male/female) | FDA_Toxicity_c3e27a4e-2099-431d-aab3-92c709024c1d_dossier.i6z |
| <=0.05 | % | NOEL | dermal | mouse (CD-1; male/female) | FDA_Toxicity_c3e27a4e-2099-431d-aab3-92c709024c1d_dossier.i6z |
| <=0.05 | mg/kg bw/day | NOEL | dermal | rat (Sprague-Dawley; male/female) | FDA_Toxicity_c3e27a4e-2099-431d-aab3-92c709024c1d_dossier.i6z |
| <=0.05 | % | NOEL | dermal | mouse (CD-1; male/female) | FDA_Toxicity_c3e27a4e-2099-431d-aab3-92c709024c1d_dossier.i6z |
| <=0.05 | mg/kg bw/day | NOEL | dermal | rat (Sprague-Dawley; male/female) | FDA_Toxicity_c3e27a4e-2099-431d-aab3-92c709024c1d_dossier.i6z |
| <=0.05 | % | NOEL | dermal | mouse (CD-1; male/female) | FDA_Toxicity_c3e27a4e-2099-431d-aab3-92c709024c1d_dossier.i6z |
| <=0.05 | mg/kg bw/day | NOEL | dermal | rat (Sprague-Dawley; male/female) | FDA_Toxicity_c3e27a4e-2099-431d-aab3-92c709024c1d_dossier.i6z |
| <=0.1 | % | NOEL | dermal | rat (other:; male/female) | FDA_Toxicity_c3e27a4e-2099-431d-aab3-92c709024c1d_dossier.i6z |
| <=0.1 | % | NOEL | dermal | rat (other:; male/female) | FDA_Toxicity_c3e27a4e-2099-431d-aab3-92c709024c1d_dossier.i6z |
| <=0.1 | % | NOEL | dermal | rat (other:; male/female) | FDA_Toxicity_c3e27a4e-2099-431d-aab3-92c709024c1d_dossier.i6z |
| <=0.1 | % | NOEL | dermal | rat (other:; male/female) | FDA_Toxicity_c3e27a4e-2099-431d-aab3-92c709024c1d_dossier.i6z |
| <=0.125 | mg/kg bw/day | NOEL | dermal | rat (Sprague-Dawley; male/female) | FDA_Toxicity_c3e27a4e-2099-431d-aab3-92c709024c1d_dossier.i6z |
| <=0.125 | mg/kg bw/day | NOEL | dermal | rat (Sprague-Dawley; male/female) | FDA_Toxicity_c3e27a4e-2099-431d-aab3-92c709024c1d_dossier.i6z |
| <=0.125 | mg/kg bw/day | NOEL | dermal | rat (Sprague-Dawley; male/female) | FDA_Toxicity_c3e27a4e-2099-431d-aab3-92c709024c1d_dossier.i6z |
| <=0.125 | mg/kg bw/day | NOEL | dermal | rat (Sprague-Dawley; male/female) | FDA_Toxicity_c3e27a4e-2099-431d-aab3-92c709024c1d_dossier.i6z |
| <=0.25 | mg/kg bw/day | NOEL | dermal | Pig | ToxValDB_ECHA_IUCLID |
| <=0.25 | mg/kg bw/day | NOEL | dermal | rabbit (New Zealand White; male/female) | FDA_Toxicity_c3e27a4e-2099-431d-aab3-92c709024c1d_dossier.i6z |
| <=0.25 | mg/kg bw/day | NOEL | dermal | rabbit (New Zealand White; male/female) | FDA_Toxicity_c3e27a4e-2099-431d-aab3-92c709024c1d_dossier.i6z |
| <=0.25 | mg/kg bw/day | NOEL | dermal | rabbit (New Zealand White; male/female) | FDA_Toxicity_c3e27a4e-2099-431d-aab3-92c709024c1d_dossier.i6z |
| <=0.25 | mg/kg bw/day | NOEL | dermal | rabbit (New Zealand White; male/female) | FDA_Toxicity_c3e27a4e-2099-431d-aab3-92c709024c1d_dossier.i6z |
| <=0.5 | mg/kg bw/day | NOEL | oral | Monkey | ToxValDB_ECHA_IUCLID |
| <=0.5 | mg/kg bw/day | NOEL | dermal | rat (Sprague-Dawley; male/female) | FDA_Toxicity_c3e27a4e-2099-431d-aab3-92c709024c1d_dossier.i6z |
| <=0.5 | mg/kg bw/day | NOEL | dermal | rat (Sprague-Dawley; male/female) | FDA_Toxicity_c3e27a4e-2099-431d-aab3-92c709024c1d_dossier.i6z |
| <=0.5 | mg/kg bw/day | NOEL | dermal | rat (Sprague-Dawley; male/female) | FDA_Toxicity_c3e27a4e-2099-431d-aab3-92c709024c1d_dossier.i6z |
| <=0.5 | mg/kg bw/day | NOEL | dermal | rat (Sprague-Dawley; male/female) | FDA_Toxicity_c3e27a4e-2099-431d-aab3-92c709024c1d_dossier.i6z |
| >=1 | mg/kg bw/day | NOEL | oral: unspecified | rat (Sprague-Dawley) | FDA_Toxicity_c3e27a4e-2099-431d-aab3-92c709024c1d_dossier.i6z |
| >=1 | mg/kg bw/day | NOEL | oral: unspecified | rat (Sprague-Dawley) | FDA_Toxicity_c3e27a4e-2099-431d-aab3-92c709024c1d_dossier.i6z |
| >=1 | mg/kg bw/day | NOEL | oral: unspecified | rat (Sprague-Dawley) | FDA_Toxicity_c3e27a4e-2099-431d-aab3-92c709024c1d_dossier.i6z |
| >=1 | mg/kg bw/day | NOEL | oral: unspecified | rat (Sprague-Dawley) | FDA_Toxicity_c3e27a4e-2099-431d-aab3-92c709024c1d_dossier.i6z |
Showing 42 of 42 studies
Cosmetic Safety Profile
Same-CAS cosmetic ingredient record for cross-vertical context.
SOURCE
CosIng / Ingredients DB
EU Status
restricted
Max
Prescription only
Category
active
Pharmaceutical Data
Same-CAS pharmaceutical records from drug and bioactivity sources.
SOURCE
EMBL-EBI ChEMBL
TAZAROTENE
ChEMBL Phase
4
Adverse Events
133
Bioactivity
7
Frequently Asked Questions
What regulatory lists include Tazarotene?
Tazarotene appears on 3 regulatory/inventory lists including Canada; consumer_product; Substances in Products - Canada (4/2014), pharmaceutical, Canada; pharmaceutical. Source: EPA CPDat.
Is Tazarotene used in cosmetics?
Yes, Tazarotene is also indexed as a cosmetic ingredient under the name Tazarotene. View the full cosmetic safety profile on the ingredient page for detailed safety data, SCCS opinions, and regulatory status.
Where does the safety data for Tazarotene come from?
Safety data is sourced from EPA ToxValDB, EPA CPDat, EPA DSSTox, CosIng / Ingredients DB, ChEMBL / DailyMed. All data traces to primary regulatory sources and is updated from official government databases.
Is Tazarotene used outside industrial chemicals?
Tazarotene also appears in cosmetics, pharmaceutical databases.